DOCSLIB.ORG

Determination of Iodinated Contrast Media in Aqueous Samples by Direct-Injection LC-MS/MS

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Determination of Iodinated Contrast Media in Aqueous Samples by Direct-Injection LC-MS/MS Determination of Iodinated Contrast Media in Aqueous Samples by Direct-Injection LC-MS/MS Application Note Environmental Authors Abstract Gerd Vanhoenacker, Mieke Steenbeke, Determination of iodinated contrast media in aqueous samples was performed by Frank David, and Pat Sandra fast chromatography on an Agilent 1290 Infi nity II LC that included an Agilent 1290 Research Institute for Chromatography Infi nity II Multisampler equipped with a 100 µL analytical head and loop cartridge. President Kennedypark 26 Detection was done with an Agilent 6495 Triple Quadrupole LC/MS. With this B-8500 Kortrijk confi guration, it was possible to detect the contrast agents at the low ng/L parts Belgium per trillion (ppt) level in water without any pretreatment except fi ltration. The method was developed for seven target contrast agents, and the performance Udo Huber and fi gures of merit were investigated on standard solutions as well as on various Agilent Technologies, Inc. water samples. Waldbronn, Germany Introduction The analysis of ICMs in the environment This Application Note describes the use has gained considerable interest over the of the Agilent 6495 Triple Quadrupole Iodinated contrast media (ICMs) are last decade. Earlier approaches measured LC/MS in combination with the globally used for medical X-ray imaging. the total absorbable organic iodine (AOI), Agilent 1290 Infi nity II LC for the direct These iodine-based chemicals are whereas recent methods focus on the analysis of selected ICMs (Figure 1) in administered intravascularly, and absorb sensitive detection of individual ICMs water samples at low ng/L (ppt) levels. X-rays in vessels and tissues, enhancing and potential degradation products by Direct injection of water samples without the visibility of internal structures. LC-MS and LC-MS/MS1-4,8. These polar any pretreatment except fi ltration was Several ICMs are available. This class and sometimes acidic compounds can applied. Relatively large volumes need to of pharmaceuticals is one of the most suffer from bad peak shapes in LC, and be injected, requiring adequate control of frequently used groups of chemicals the chromatographic parameters need the separation conditions. State-of-the-art applied in hospitals, and generally at to be carefully chosen. To meet low mass spectrometry offers high sensitivity, relatively high doses1. ng/L (part per trillion, ppt) detection allowing direct analysis of trace Signifi cant levels can be found in various limits, an extraction step such as contaminants in water. This reduces time aqueous matrices (hospital wastewater1-3, solid-phase extraction (SPE) is commonly and cost per analysis, and minimizes 1,9 surface water2, ground water4,5, and performed . errors that can be made during sample even drinking water5), and soil6. Studies pretreatment. have demonstrated that complete ICM removal in wastewater treatment plants OH OH is diffi cult or even impossible with state-of-the-art water treatment methods OH H O NH such as ozonation, UV irradiation, O N OH chlorination, microbial degradation, I I I I OH 1,2 OH H O and so on . Consequently, they are H O N OH frequently detected at signifi cant levels HO N OH N N H in wastewater treatment plant effl uents. O I O I HO Moreover, potentially toxic iodine derivatives can be formed and released Iomeprol Iopamidol 7 into the environment upon treatment . OH H OH O N OH H O N OH I I OH H O I I OH HO N O N HO N O O N I OH H O I OH Iohexol Iopromide H O OH N O O OH I I I I II O O H O H O N N HO N N N N H H H O I O I I Ioxaglic acid Diatrizoic acid O OH I I H O N HNO H O I Ioxitalamic acid Figure 1. Structures of the studied ICMs. 2 Experimental Method parameters Instrumentation Parameter Description An Agilent 1290 Infi nity II LC and an Mobile phase A) 0.1 % (v/v) acetic acid in water Agilent 6495 Triple Quadrupole MS with B) Acetonitrile an Agilent Jet Stream technology source Flow rate 0.4 mL/min were used. The 1290 Infi nity II LC was Gradient 0 to 1 minutes – 0 %B confi gured as follows: 1 to 5 minutes – 0 to 73 %B 5 to 5.5 minutes – 73 to 95 %B • Agilent 1290 Infi nity II High Speed 5.5 to 7 minutes – 95 %B Pump (G7120A) with a 35 µL Jet Post time 3 minutes at 0 %B Weaver mixer Temperature 15 °C Injection 100 µL, with needle wash (fl ush port, 5 seconds, water/methanol 1/1) • Agilent 1290 Infi nity II Multisampler (G7167B) Detection parameters with analytical head 100 µL Parameter Description (G4267-60043) and sample Mode MS/MS loop-fl ex 100 µL (G4267-60500) Ionization Electrospray, positive ionization • Agilent 1290 Infi nity II Multicolumn Drying gas temperature 220 °C Thermostat (G7116B) with an Drying gas fl ow 13 L/min Agilent Infi nityLab Quick Connect Nebulizer pressure 40 psig heat exchanger assembly for Sheath gas temperature 390 °C standard fl ow (G7116-60015), Sheath gas fl ow 11 L/min Infi nityLab Quick Connect fi ttings Capillary voltage 3,500 V 0.12 × 105 mm (5067-5957), and Nozzle voltage 1,600 V an Agilent ZORBAX Eclipse Plus Dynamic MRM See Table 1 C18 RRHD, 2.1 × 150 mm, 1.8 µm Delta EMV 200 column (959759-902) Cycle time 200 ms 0 to 3 minutes – Waste 3 to 5 minutes – MS 5 minutes to end – Waste 3 Table 1 shows the acquisition parameters Separate stock solutions of the standards Water samples were stored at 4 °C. After for the selected ICMs. and internal standards were prepared removal from the refrigerator, they were in methanol/water 50/50 v/v at 5 and allowed to reach room temperature, Solutions and samples 1 mg/L (ppm), respectively. These then agitated. An aliquot was taken, solutions were diluted to 100 µg/L (ppb) and an internal standard was added. The ICMs were purchased from LGC working solutions in methanol/water For the spiking experiments, a stock Standards SARL (Molsheim, France), 10/90 v/v. All subsequent dilutions were solution of the ICMs was added. A and deuterated internal standards were made in deionized HPLC water. portion of the water sample was fi ltered provided by an Agilent customer, but can through a syringe fi lter (Captiva Premium be ordered, for example, from Santa Cruz Syringe Filter Regenerated Cellulose, Biotechnology, Inc., Dallas, Texas. 25 mm, 0.45 µm, Agilent Technologies, p/n 5190-5111) into an autosampler vial. Table 1. Dynamic MRM acquisition parameters for the compounds under investigation. The fi rst transition is the quantifi er transition. Precursor MS1 Product MS2 RT RT Window Collision Compound ion (m/z) Resolution ion (m/z) Resolution (min) (min) energy (V) Cell accelerator voltage Iopamidol 777.9 Unit 541.9 Wide 3.73 1 32 3.5 777.9 Unit 558.9 Wide 3.73 1 24 3.5 777.9 Unit 386.9 Wide 3.73 1 42 1 Ioxitalamic acid 662.0 Unit 645.0 Wide 3.76 1 5 3 662.0 Unit 429.0 Wide 3.76 1 33 3 662.0 Unit 302.0 Wide 3.76 1 50 3 Iohexol 821.9 Unit 803.9 Wide 3.80 1 24 1.5 821.9 Unit 656.9 Wide 3.80 1 30 1 821.9 Unit 375.0 Wide 3.80 1 52 6 Iomeprol 777.8 Unit 404.8 Wide 3.73 1 44 3.5 777.8 Unit 558.7 Wide 3.73 1 28 3.5 777.8 Unit 532.0 Wide 3.73 1 22 3.5 Diatrizoic acid 614.8 Unit 360.4 Wide 3.88 1 25 1 614.9 Unit 233.0 Wide 3.88 1 47 3 Iopromide 792.0 Unit 573.0 Wide 4.04 1 28 2 792.0 Unit 558.9 Wide 4.04 1 28 2 Ioxaglic acid 1269.6 Wide 610.8 Wide 4.51 1 40 2 1269.6 Wide 455.9 Wide 4.51 1 60 5.5 Internal standards Iopamidol-D8 786.0 Unit 391.0 Wide 3.73 1 42 1 786.0 Unit 546.0 Wide 3.73 1 32 3.5 Iohexol-D5 826.9 Unit 809.0 Wide 3.80 1 20 1.5 Iomeprol-D3 781.0 Unit 562.0 Wide 3.86 1 22 3.5 781.0 Unit 535.0 Wide 3.86 1 22 3.5 Iopromide-D3 795.1 Unit 576.0 Wide 4.03 1 28 2 795.1 Unit 299.9 Wide 4.03 1 28 2 4 Results and Discussion ×103 5.5 A The selected ICMs are highly polar, 4 5 6 1. Iopamidol (777.9 & 558.9) and the analytical conditions had to be 5.0 2. Ioxitalamic acid (662.0 & 645.0) 3. Iohexol (821.9 & 803.9) carefully chosen to obtain adequate 4.5 4. Iomeprol (777.8 & 404.8) retention, acceptable peak shape, and 5. Diatrizoic acid (614.8 & 360.4) 4.0 6. Iopromide (792.0 & 573.0) good effi ciency. Moreover, care had to 1 7. Ioxaglic acid (1,269.6 & 610.8) be taken so that the sensitivity of the 3.5 mass spectrometer was not affected by 3.0 the choice of the mobile phase. All LC parameters were carefully optimized, and Counts 2.5 reversed-phase LC with a mobile phase 2.0 of acetic acid in water and acetonitrile 1.5 3 2 7 proved to give the best overall results in *2786 terms of chromatography and detection.
Load more

Recommended publications
  • In Cooperation with Proficiency Test 8/18 TW S6 – X-Ray- and MRT-Contrast Media in Drinking Water Dear Madam Or Sir, In
    Institute for Sanitary Engineering, Water Quality and Solid Waste Management AQS Baden-Württemberg Universit y of Stuttgart ● ISWA ● Bandtäle 2 ● 70569 Stuttgart Contact person AQS Baden-Württemberg Dr. Frank Baumeister, Dr. Michael Koch, Mandy Wünsche To the participants of AQS Baden-Württemberg Contact details Bandtäle 2 70569 Stuttgart GERMANY T +49 711 685-65446 F +49 711 685-63769 [email protected] www.aqsbw.de Proficiency test 8/18 TW S6 – X-ray- and MRT-contrast media in drinking water 2018-06-22 Dear Madam or Sir, in September 2018 the execution of the above mentioned proficiency test (PT) round „X-ray- and MRT-contrast media in drinking water” is planned. The PT is carried out under the umbrella of the NORMAN Network of Reference Laboratories for Monitoring of Emerging Environmental Pollutants (http://www.norman-network.net) in cooperation with IWW Water Centre. Details about the PT round are enclosed. Please read them with care. If you are interested in participation, please register online via our website http://www.iswa.uni-stuttgart.de/ch/aqs/rv/anm_rv.en.php?id=181. You will receive a confirmation of receipt by e-mail. With a second e- mail we will bindingly confirm your application to the PT. You are not registered if you do not receive any e-mail. Application deadline: 24 July 2018 Please consider our general terms and conditions of business for the execution of the PT, which can be downloaded from http://www.aqsbw.de/pdf/agb_en.pdf. Bank Baden-Württembergische If we receive your application after the deadline we cannot guarantee Bank Stuttgart – BW-Bank that participation will be possible.
    [Show full text]
  • Published Version
    Chapter 12 Water quality analysis: Detection, fate, and behaviour, of selected trace organic pollutants at managed aquifer recharge sites Mathias Ernst, Arne Hein, Josef Asmin, Martin Krauss, Guido Fink, Juliane Hollender, Thomas Ternes, Claus Jørgensen, Martin Jekel and Christa S. McArdell 12.1 INTRODUCTION In treated municipal wastewater, residual organic compounds are of high relevance especially if water recycling and potable water reuse is envisaged. After biological treatment, such as the activated sludge process, some organic compounds remain that are either non-biodegradable, or are minimally biodegradable. If these chemicals are polar, they are commonly poorly absorbable, and are therefore identified as persistent polar organic compounds (also persistent polar pollutants, PPPs). In the last decade, there have been important analytical improvements in detecting trace levels of pollutants, and within the water reuse community, new “hazardous” compounds are frequently discussed. This includes consideration of which organic residuals are really of health concern, which transformation products can be generated, and what is their human and environmental impact? Within the present chapter relevant PPPs and their fate during (advanced) wastewater treatment and managed aquifer recharge are identified and discussed as results of measuring campaigns at technologically different demonstration sites within the European research project RECLAIM WATER. Such PPPs mainly belong in the group of pharmaceuticals but also industrial chemicals. Here antibiotics such as the macrolides and sulfonamides are of particular concern, because of the eco-toxicological potential of these parent micropollutants, and the potential threat posed by the build-up of antibiotic resistance genes. In addition to known multi-resistant bacteria such as Staphylococci, multi-resistant genes have recently been identified in the intestinal bacteria Citrobacter, Enterobacteriaceae and Escherichia coli (Patoli et al.
    [Show full text]
  • 201277Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 201277Orig1s000 OTHER REVIEW(S) PMR/PMC Development Template This template should be completed by the PMR/PMC Development Coordinator and included for each PMR/PMC in the Action Package. PMR/PMC Description: DARRTS Set #1743-1 A study that will examine the safety of Gadavist in new born and neonates animals, following a single dose and limited repeated dose administrations. The study will provide safety data assessing mortality, toxicities, and potential reversibility of observed clinical and histopathological findings. The study will also examine the pharmacokinetics of Gadavist including tissue deposition of Gadolinium. PMR/PMC Schedule Milestones: Final Protocol Submission: May, 2011 Study/Trial Completion: January, 2012 Final Report Submission: June, 2012 Other: 1. During application review, explain why this issue is appropriate for a PMR/PMC instead of a pre-approval requirement. Check type below and describe. Unmet need Life-threatening condition Long-term data needed Only feasible to conduct post-approval (I removed this check on the nonclinical form) Prior clinical experience indicates safety Small subpopulation affected (I removed this check on the nonclinical form) Theoretical concern Other Proposed nonclinical study will evaluate the safety of Gadavist in a non clinical animal model prior to clinical exposure in view of known risk of NSF in adults especially those with renal impairment. 2. Describe the particular review issue and the goal of the study/clinical trial. If the study/clinical trial is a FDAAA PMR, describe the risk. If the FDAAA PMR is created post-approval, describe the “new safety information.” ReferencePMR/PMC ID: 2918081Development Template Last Updated 3/14/2011 Page 1 of 4 To evaluate the safety of Gadavist in newborn and neonate animals.
    [Show full text]
  • Xx250 Spc 2015 Uk
    SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT XENETIX 250 (250 mgI/ml) Solution for injection. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION per ml 50 ml 100 ml 200 ml 500 ml Iobitridol (INN) 548.4 mg 27.42 g 54.84 g 109.68 g 274.2 g Iodine corresponding to 250 mg 12.5 g 25 g 50 g 125 g Excipient with known effect : Sodium (up to 3.5 mg per 100 mL). For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. Clear, colourless to pale yellow solution 4. CLINICAL PARTICULARS 4.1. Therapeutic indications For adults and children undergoing: . whole-body CT . venography . intra-arterial digital subtraction angiography . ERP/ERCP This medicinal product is for diagnostic use only. 4.2. Posology and method of administration The dosage may vary depending on the type of examination, the age, weight, cardiac output and general condition of the patient and the technique used. Usually the same iodine concentration and volume are used as with other iodinated X-ray contrast in current use. As with all contrast media, the lowest dose necessary to obtain adequate visualisation should be used. Adequate hydration should be assured before and after administration as for other contrast media. As a guideline, the recommended dosages are as follows: Indications Recommended dosage Whole-body CT The doses of contrast medium and the rates of administration depend on the organs under investigation, the diagnostic problem and, in particular, the different scan and image-reconstruction times of the scanners in use.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Pharmacologyonline 2: 727-753 (2010) Ewsletter Bradu and Rossini
    Pharmacologyonline 2: 727-753 (2010) ewsletter Bradu and Rossini COTRAST AGETS - IODIATED PRODUCTS. SECOD WHO-ITA / ITA-OMS 2010 COTRIBUTIO O AGGREGATE WHO SYSTEM-ORGA CLASS DISORDERS AD/OR CLUSTERIG BASED O REPORTED ADVERSE REACTIOS/EVETS Dan Bradu and Luigi Rossini* Servizio Nazionale Collaborativo WHO-ITA / ITA-OMS, Università Politecnica delle Marche e Progetto di Farmacotossicovigilanza, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Regione Marche, Italia Summary From the 2010 total basic adverse reactions and events collected as ADRs preferred names in the WHO-Uppsala Drug Monitoring Programme, subdivided in its first two twenty years periods as for the first seven iodinated products diagnostic contrast agents amidotrizoate, iodamide, iotalamate, iodoxamate, ioxaglate, iohexsol and iopamidol, their 30 WHO-system organ class disorders (SOCDs) aggregates had been compared. Their common maximum 97% levels identified six SOCDs only, apt to evaluate the most frequent single ADRs for each class, and their percentual normalization profiles for each product. The WILKS's chi square statistics for the related contingency tables, and Gabriel’s STP procedure applied to the extracted double data sets then produced profile binary clustering, as well as Euclidean confirmatory plots. They finally showed similar objectively evaluated autoclassificative trends of these products, which do not completely correspond to their actual ATC V08A A, B and C subdivision: while amidotrizoate and iotalamate, and respectively iohesol and iopamidol are confirmed to belong to the A and B subgroups, ioxaglate behaves fluctuating within A, B and C, but iodamide looks surprizingly, constantly positioned together with iodoxamate as binary/ternary C associated. In view of the recent work of Campillos et al (Science, 2008) which throws light on the subject, the above discrepancies do not appear anymore unexpected or alarming.
    [Show full text]
  • Drug-Induced Anaphylaxis in China: a 10 Year Retrospective Analysis of The
    Int J Clin Pharm DOI 10.1007/s11096-017-0535-2 RESEARCH ARTICLE Drug‑induced anaphylaxis in China: a 10 year retrospective analysis of the Beijing Pharmacovigilance Database Ying Zhao1,2,3 · Shusen Sun4 · Xiaotong Li1,3 · Xiang Ma1 · Huilin Tang5 · Lulu Sun2 · Suodi Zhai1 · Tiansheng Wang1,3,6 Received: 9 May 2017 / Accepted: 19 September 2017 © The Author(s) 2017. This article is an open access publication Abstract Background Few studies on the causes of (50.1%), mucocutaneous (47.4%), and gastrointestinal symp- drug-induced anaphylaxis (DIA) in the hospital setting are toms (31.3%). A total of 249 diferent drugs were involved. available. Objective We aimed to use the Beijing Pharma- DIAs were mainly caused by antibiotics (39.3%), traditional covigilance Database (BPD) to identify the causes of DIA Chinese medicines (TCM) (11.9%), radiocontrast agents in Beijing, China. Setting Anaphylactic case reports from (11.9%), and antineoplastic agents (10.3%). Cephalospor- the BPD provided by the Beijing Center for Adverse Drug ins accounted for majority (34.5%) of antibiotic-induced Reaction Monitoring. Method DIA cases collected by the anaphylaxis, followed by fuoroquinolones (29.6%), beta- BPD from January 2004 to December 2014 were adjudi- lactam/beta-lactamase inhibitors (15.4%) and penicillins cated. Cases were analyzed for demographics, causative (7.9%). Blood products and biological agents (3.1%), and drugs and route of administration, and clinical signs and plasma substitutes (2.1%) were also important contributors outcomes. Main outcome measure Drugs implicated in DIAs to DIAs. Conclusion A variety of drug classes were impli- were identifed and the signs and symptoms of the DIA cases cated in DIAs.
    [Show full text]
  • NON-HAZARDOUS CHEMICALS May Be Disposed of Via Sanitary Sewer Or Solid Waste
    NON-HAZARDOUS CHEMICALS May Be Disposed Of Via Sanitary Sewer or Solid Waste (+)-A-TOCOPHEROL ACID SUCCINATE (+,-)-VERAPAMIL, HYDROCHLORIDE 1-AMINOANTHRAQUINONE 1-AMINO-1-CYCLOHEXANECARBOXYLIC ACID 1-BROMOOCTADECANE 1-CARBOXYNAPHTHALENE 1-DECENE 1-HYDROXYANTHRAQUINONE 1-METHYL-4-PHENYL-1,2,5,6-TETRAHYDROPYRIDINE HYDROCHLORIDE 1-NONENE 1-TETRADECENE 1-THIO-B-D-GLUCOSE 1-TRIDECENE 1-UNDECENE 2-ACETAMIDO-1-AZIDO-1,2-DIDEOXY-B-D-GLYCOPYRANOSE 2-ACETAMIDOACRYLIC ACID 2-AMINO-4-CHLOROBENZOTHIAZOLE 2-AMINO-2-(HYDROXY METHYL)-1,3-PROPONEDIOL 2-AMINOBENZOTHIAZOLE 2-AMINOIMIDAZOLE 2-AMINO-5-METHYLBENZENESULFONIC ACID 2-AMINOPURINE 2-ANILINOETHANOL 2-BUTENE-1,4-DIOL 2-CHLOROBENZYLALCOHOL 2-DEOXYCYTIDINE 5-MONOPHOSPHATE 2-DEOXY-D-GLUCOSE 2-DEOXY-D-RIBOSE 2'-DEOXYURIDINE 2'-DEOXYURIDINE 5'-MONOPHOSPHATE 2-HYDROETHYL ACETATE 2-HYDROXY-4-(METHYLTHIO)BUTYRIC ACID 2-METHYLFLUORENE 2-METHYL-2-THIOPSEUDOUREA SULFATE 2-MORPHOLINOETHANESULFONIC ACID 2-NAPHTHOIC ACID 2-OXYGLUTARIC ACID 2-PHENYLPROPIONIC ACID 2-PYRIDINEALDOXIME METHIODIDE 2-STEP CHEMISTRY STEP 1 PART D 2-STEP CHEMISTRY STEP 2 PART A 2-THIOLHISTIDINE 2-THIOPHENECARBOXYLIC ACID 2-THIOPHENECARBOXYLIC HYDRAZIDE 3-ACETYLINDOLE 3-AMINO-1,2,4-TRIAZINE 3-AMINO-L-TYROSINE DIHYDROCHLORIDE MONOHYDRATE 3-CARBETHOXY-2-PIPERIDONE 3-CHLOROCYCLOBUTANONE SOLUTION 3-CHLORO-2-NITROBENZOIC ACID 3-(DIETHYLAMINO)-7-[[P-(DIMETHYLAMINO)PHENYL]AZO]-5-PHENAZINIUM CHLORIDE 3-HYDROXYTROSINE 1 9/26/2005 NON-HAZARDOUS CHEMICALS May Be Disposed Of Via Sanitary Sewer or Solid Waste 3-HYDROXYTYRAMINE HYDROCHLORIDE 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE
    [Show full text]
  • Page 1 Note: Within Nine Months from the Publication of the Mention
    Europäisches Patentamt (19) European Patent Office & Office européen des brevets (11) EP 1 411 992 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 49/04 (2006.01) A61K 49/18 (2006.01) 13.12.2006 Bulletin 2006/50 (86) International application number: (21) Application number: 02758379.8 PCT/EP2002/008183 (22) Date of filing: 23.07.2002 (87) International publication number: WO 2003/013616 (20.02.2003 Gazette 2003/08) (54) IONIC AND NON-IONIC RADIOGRAPHIC CONTRAST AGENTS FOR USE IN COMBINED X-RAY AND NUCLEAR MAGNETIC RESONANCE DIAGNOSTICS IONISCHES UND NICHT-IONISCHES RADIOGRAPHISCHES KONTRASTMITTEL ZUR VERWENDUNG IN DER KOMBINIERTEN ROENTGEN- UND KERNSPINTOMOGRAPHIEDIAGNOSTIK SUBSTANCES IONIQUES ET NON-IONIQUES DE CONTRASTE RADIOGRAPHIQUE UTILISEES POUR ETABLIR DES DIAGNOSTICS FAISANT APPEL AUX RAYONS X ET A L’IMAGERIE PAR RESONANCE MAGNETIQUE (84) Designated Contracting States: (74) Representative: Minoja, Fabrizio AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Bianchetti Bracco Minoja S.r.l. IE IT LI LU MC NL PT SE SK TR Via Plinio, 63 20129 Milano (IT) (30) Priority: 03.08.2001 IT MI20011706 (56) References cited: (43) Date of publication of application: EP-A- 0 759 785 WO-A-00/75141 28.04.2004 Bulletin 2004/18 US-A- 5 648 536 (73) Proprietor: BRACCO IMAGING S.p.A. • K HERGAN, W. DORINGER, M. LÄNGLE W.OSER: 20134 Milano (IT) "Effects of iodinated contrast agents in MR imaging" EUROPEAN JOURNAL OF (72) Inventors: RADIOLOGY, vol. 21, 1995, pages 11-17, • AIME, Silvio XP002227102 20134 Milano (IT) • K.M.
    [Show full text]
  • Harmonised Bds Suppl 20070
    ABCDEF 1 EU Harmonised Birth Dates and related Data Lock Points, Supplementary list, 7 February 2007 Innovator brand name First DLP after Proposed Active substance name (INN) (for fixed combination 30 October Firm's Name Comments EU HBD products only) 2005 2 3 Aceclofenac 19900319 20080331 Almirall / UCB 4 Aciclovir 19810610 20060630 GSK 5 Adrafinil 19810710 20060131 Cephalon 6 Aldesleukine 19890703 20051231 Novartis NL=RMS Pfizer/Schwarz 7 Alprostadil (erectile dysfunction) 19840128 20080131 Pharma UK=RMS Alprostadil (peripheral arterial 19810723 20060731 Pfizer product differs from Schwarz Pharma 8 occlusive diseases) product Alprostadil (peripheral arterial 19841128 20051128 Schwarz Pharma product differs from Pfizer product 9 occlusive diseases) 10 Atenolol + chlorthalidone Tenoretic 19970909 20080908 AstraZeneca Azelaic acid 19881027 20060102 Schering AG / Pfizer AT = RMS 11 12 Aztreonam 19840804 20060803 BMS 13 Benazepril 19891128 20071130 Novartis Benazepril + hydrochlorothiazide Cibadrex 19920519 20070531 Novartis 14 15 Bisoprolol 19860128 20070930 Merck AG Bisoprolol + hydrochlorothiazide many product names 19920130 20061103 Merck AG 16 17 Botulinum Toxin A 19960906 20061030 Allergan currently 6-monthly PSURs 18 Brimonidine 19960906 20080930 Allergan UK=RMS 19 Brimonidine + timolol Combigan 19960906 20080930 Allergan UK=RMS 20 Bromperidol 20061115 J&J 21 Brotizolam 19830515 20071231 Boehringer Ingelheim 22 Budesonide 19920430 20070430 AstraZeneca 23 Budesonide + formoterol Symbicort 20000825 20070825 AstraZeneca 24 Buflomedil
    [Show full text]
  • ACR Manual on Contrast Media
    ACR Manual On Contrast Media 2021 ACR Committee on Drugs and Contrast Media Preface 2 ACR Manual on Contrast Media 2021 ACR Committee on Drugs and Contrast Media © Copyright 2021 American College of Radiology ISBN: 978-1-55903-012-0 TABLE OF CONTENTS Topic Page 1. Preface 1 2. Version History 2 3. Introduction 4 4. Patient Selection and Preparation Strategies Before Contrast 5 Medium Administration 5. Fasting Prior to Intravascular Contrast Media Administration 14 6. Safe Injection of Contrast Media 15 7. Extravasation of Contrast Media 18 8. Allergic-Like And Physiologic Reactions to Intravascular 22 Iodinated Contrast Media 9. Contrast Media Warming 29 10. Contrast-Associated Acute Kidney Injury and Contrast 33 Induced Acute Kidney Injury in Adults 11. Metformin 45 12. Contrast Media in Children 48 13. Gastrointestinal (GI) Contrast Media in Adults: Indications and 57 Guidelines 14. ACR–ASNR Position Statement On the Use of Gadolinium 78 Contrast Agents 15. Adverse Reactions To Gadolinium-Based Contrast Media 79 16. Nephrogenic Systemic Fibrosis (NSF) 83 17. Ultrasound Contrast Media 92 18. Treatment of Contrast Reactions 95 19. Administration of Contrast Media to Pregnant or Potentially 97 Pregnant Patients 20. Administration of Contrast Media to Women Who are Breast- 101 Feeding Table 1 – Categories Of Acute Reactions 103 Table 2 – Treatment Of Acute Reactions To Contrast Media In 105 Children Table 3 – Management Of Acute Reactions To Contrast Media In 114 Adults Table 4 – Equipment For Contrast Reaction Kits In Radiology 122 Appendix A – Contrast Media Specifications 124 PREFACE This edition of the ACR Manual on Contrast Media replaces all earlier editions.
    [Show full text]